Pay Attention to What You Focus on

By -
This is, by far, the worst crap, er, crop I’ve ever grown.  Frickin' spider mites come back every three days. I've hit them will sulfur, and organic sprays that won't hurt the delicate THC crystals growing within. But still the yellow specks remain and all I want to do is take a firehose to the plants and wash them away. But there’s carpet under that visqueen, and wallpaper behind that sheetrocked wall. I have no firehose.


It’s obvious to any grower that I didn’t provide enough nutrients during vegetative growth. The girls are tall and skinny, gangly in appearance. They bent and fall over – like druken soriety sisters.t. Part of me is angry with myself for letting this happen, “I should have raised them better.”


But just like anything, including children, if you take your eyes of them for a minute, all hell beaks loose. Whatever you pay attention to, gets the most focus. Lately I’ve been too distracted working with industry people trying to find their way under I-502. Today I spoke to a woman looking for 4,000 feet of warehouse space; another needs more security cameras to pass inspection – within 24 hours. Media people are coming to town, everyone’s jockeying for position. This is going to be a long and bumpy ride. I only hope my crop can take it!

Comments

Post a Comment

Popular posts from this blog

Hempy 2014!

By -
Image
I started 2013 with a basement full of weed and an empty bank account. I don’t know of any Seattle growers that actually got rich from growing pot this year. I think a lot of us unemployed corporate types who were laid off saw the opportunity to work for ourselves until the state could figure out what to do with the future of medical and voter approved recreational pot. A year later, the future of  medical marijuana in Washington State is still tenuous.  I have personally witnessed healing in people who use cannabis as medicine and I think it’s a crime that providers have been thrown in jail for helping others. Cannabis IS medicine and we have a God-given right to have access to it. Dispensary “donations” were my main source of income in 2013. I make half of what I used to back in my VC-funded days, but I don’t care. Money is not it. Helping people, and loving what you do on a daily basis where it’s at, man. The meaning of life is to be of service to others. Working
Read more

Coming Out of the Pot Closet

By -
Image
I have to vacuum before my mother arrives from Arizona. I’m 40-something years old and I still want her housekeeping approval. While we’re close, and speak on the phone every week, we haven’t seen each other 1:1 for a while. I’m freaking out because I think she’ll have an aneurysm when I tell her how I’ve been paying my bills the past three years. Garden of Eve The time has arrived for me to come out of the Pot Closet to my mother. How did I get here? I was laid off from my event-planning job while dating a “normal-looking” guy, who owned his own landscaping business. “Larry” also happen to own a basement full of marijuana plants for extra spending money (on prostitutes, as it turns out, but that’s a different blog post). He taught me everything I know about being a Pharmer -- from cloning and transplanting, to providing my babies with the proper nutrients and watering techniques.  I learned a lot – about the miraculous cannabis plant, and about the lying, cheating asshol
Read more

PureTech Provides End of Year Report on Key Progress

By -
Image
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today reported on the key progress made across its Wholly Owned Programs1 and Founded Entities2 in 2022. Daphne Zohar, Founder and Chief Executive Officer of PureTech, commented: “2022 has been a particularly successful and productive year in both crystallizing value and shaping the future of PureTech. Our primary focus is to progress our Wholly Owned Pipeline to commercialization and deliver new classes of medicines for patients with serious, debilitating conditions. We are advancing toward this goal by deepening our commitment to programs with compelling clinical data that are moving into late-stage studies and that we believe have the potential for broad impact. “Over the next 12 months, we anticipate multiple important catalysts that will further guide how we prioritize o
Read more